Genomas, Inc.

Genomas, Inc. is developing novel diagnostic products to personalize disease prevention and health enhancement. The company's proprietary PhysioGenomics™ technology allows it to rapidly and precisely produce 'PhysioTypes™'. PhysioTypes are predictors of response to diet, exercise, and drugs (not diagnostics for disease), and are utilized to direct preventive strategies. A PhysioType is made from the combination of all genetic, physiological or clinical markers that Genomas has discovered to be significant determinants of individual response. PhysioTypes are revolutionary healthcare products that empower physicians with the unprecedented capability to prescribe personalized and highly effective preventive treatments, incorporating diet, exercise and drug regimens for each patient. Genomas conducts clinical research with major clinical institutions to discover these PhysioTypes with plans to commercialize them to practicing physicians and hospitals.